Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Financing Activities (2016 - 2021)

Historic Cash from Financing Activities for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $1.8 million.

  • Neurocrine Biosciences' Cash from Financing Activities rose 10097.3% to $1.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $27.4 million, marking a year-over-year increase of 11736.38%. This contributed to the annual value of -$486.7 million for FY2024, which is 84532.92% down from last year.
  • Per Neurocrine Biosciences' latest filing, its Cash from Financing Activities stood at $1.8 million for Q4 2021, which was up 10097.3% from $7.5 million recorded in Q3 2021.
  • In the past 5 years, Neurocrine Biosciences' Cash from Financing Activities registered a high of $506.5 million during Q2 2017, and its lowest value of -$185.0 million during Q4 2020.
  • For the 5-year period, Neurocrine Biosciences' Cash from Financing Activities averaged around $22.4 million, with its median value being $5.5 million (2017).
  • In the last 5 years, Neurocrine Biosciences' Cash from Financing Activities soared by 5401250.0% in 2017 and then plummeted by 159193.55% in 2020.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Cash from Financing Activities stood at $5.6 million in 2017, then crashed by 68.71% to $1.8 million in 2018, then soared by 607.76% to $12.4 million in 2019, then plummeted by 1591.94% to -$185.0 million in 2020, then skyrocketed by 100.97% to $1.8 million in 2021.
  • Its Cash from Financing Activities stands at $1.8 million for Q4 2021, versus $7.5 million for Q3 2021 and $3.0 million for Q2 2021.